Our data revealed that AZD3759 enhanced RA effects in NSCLC cells by a synergistic blockade of EGFR and JAK1, which provides the fundamental basis for the combination of AZD3759 and RA for the treatment of clinical NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.